These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 19116940)

  • 1. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
    Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
    Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
    Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
    Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
    J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.
    Ponsoye M; Frantz C; Ruzehaji N; Nicco C; Elhai M; Ruiz B; Cauvet A; Pezet S; Brandely ML; Batteux F; Allanore Y; Avouac J
    Ann Rheum Dis; 2016 Dec; 75(12):2142-2149. PubMed ID: 26912566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
    Maurer B; Distler A; Dees C; Khan K; Denton CP; Abraham D; Gay RE; Michel BA; Gay S; Hw Distler J; Distler O
    Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
    Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
    Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis.
    Reich N; Tomcik M; Zerr P; Lang V; Dees C; Avouac J; Palumbo K; Horn A; Akhmetshina A; Beyer C; Xie W; Bennett BL; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 May; 71(5):737-45. PubMed ID: 22258492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
    Vittal R; Zhang H; Han MK; Moore BB; Horowitz JC; Thannickal VJ
    J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
    Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
    Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
    Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
    Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis.
    Beyer C; Reich N; Schindler SC; Akhmetshina A; Dees C; Tomcik M; Hirth-Dietrich C; von Degenfeld G; Sandner P; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 Jun; 71(6):1019-26. PubMed ID: 22294631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis.
    Horn A; Kireva T; Palumbo-Zerr K; Dees C; Tomcik M; Cordazzo C; Zerr P; Akhmetshina A; Ruat M; Distler O; Beyer C; Schett G; Distler JH
    Ann Rheum Dis; 2012 May; 71(5):785-9. PubMed ID: 22402139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
    Beyer C; Distler JH; Distler O
    Swiss Med Wkly; 2010; 140():w13050. PubMed ID: 20419513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pomalidomide is effective for prevention and treatment of experimental skin fibrosis.
    Weingärtner S; Zerr P; Tomcik M; Palumbo-Zerr K; Distler A; Dees C; Beyer C; Shankar SL; Cedzik D; Schafer PH; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 Nov; 71(11):1895-9. PubMed ID: 22904257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
    Iwamoto N; Distler JH; Distler O
    Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
    Distler JH; Distler O
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v10-1. PubMed ID: 18784126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis.
    Avouac J; Fürnrohr BG; Tomcik M; Palumbo K; Zerr P; Horn A; Dees C; Akhmetshina A; Beyer C; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheum; 2011 Mar; 63(3):800-9. PubMed ID: 21360510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.